Healthcare Huddle
Work in healthcare? Get the industry news, insights, and analysis you need every Sunday from physician resident, Jared Dashevsky.
Created by
Jared Dashevsky, MD
MEDIA
LATEST News from Healthcare Huddle
The Great Unwind: How Governments are Preparing for the End of Continuous Enrollment
Millions of adults and children in the United States may lose their Medicaid/CHIP insurance coverage. The continuous enrollment provision of…
How The Affordable Care Act Ruined Physician-owned Hospitals
The Affordable Care Act celebrated its 13th birthday—mazel tov. It hasn’t been the easiest 13 years, though (my parents also…
The Resident’s Guide to Personal Finance
I’ve heard countless horror stories about physicians mismanaging their money right from the moment they receive their first residency paycheck….
Is the Future of U.S. Healthcare UnitedHealth Group?
Key healthcare stakeholders like payers, providers, and pharmaceutical services continue to battle harsh economic conditions caused by labor shortages and…
Are Digital Health Solutions Actually Solutions?
The digital health space is crowded with thousands of digital health companies vying for the attention of consumers, physicians, employers,…
Prescription Predicament: How Three New Models are Tackling Drug Prices
The Centers for Medicare and Medicaid Services revealed three experimental models to improve drug affordability and access. Each model is unique, targeting…
Do Weight-management Startups Have a Future?
A version of this story was published first on MedPage Today The effectiveness of GLP-1 agonists—e.g., semaglutide (Wegovy)—in reducing weight has…
From Fitness to Vital Signs: A Deep Dive into Wearable Tech
Wearable technology will soon become widespread and as regularly used as putting on shoes before leaving the house. Heck, I’m…
Looking Back, Looking Ahead: Mark Cuban’s Cost Plus Drugs Company
A version of this story was published first on MedPage Today Just over a year since its launch, Mark Cuban’s Cost Plus…
The End of the Billion-Dollar Drug
AbbVie’s Humira, the most financially successful drug in history, will be saying goodbye to its 20-year throne of U.S. market…
